Health Economics›Venous thromboembolism›VTE treatment all lines of therapy

VTE treatment all lines of therapy

Venous thromboembolism · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Enoxaparin monotherapy Variant #01	—	R 54 916	14d	—	—	~1	~R 54 916 indirect	—
Apixaban monotherapy Variant #05	—	R 2 232	180d	—	—	~1	~R 2 232 indirect	—
Fondaparinux monotherapy Variant #01	—	R 1 481	—	—	—	~1	~R 1 481 indirect	—
Rivaroxaban monotherapy Variant #05	—	R 72	90d	—	—	~1	~R 72 indirect	—
Aspirin monotherapy Variant #01	—	R 26	28d	—	—	~13	~R 340 indirect	—
Warfarin monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Heparin monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Argatroban monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Tinzaparin monotherapy Variant #01 Partial	—	—	84d	—	—	~1	—	—
Lepirudin monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Dalteparin monotherapy Variant #01 Partial	—	—	30d	—	—	~5	—	—
Bivalirudin monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Dabigatran monotherapy Variant #01 Partial	—	—	180d	—	—	~1	—	—
Edoxaban monotherapy Variant #01 Partial	—	—	360d	—	—	~1	—	—

14 of 14 regimens shown